HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sales & Earnings In Brief

This article was originally published in The Tan Sheet

Executive Summary

Cold-EEZE marketing boosts retail reorders; Prestige Brands growth refutes Genomma bid; Mannatech incentivizes new recruits; advertising adds to ChromaDex’s net loss; more Sales and Earnings In Brief.

You may also be interested in...



ChromaDex Looks To Pharma Model For Commercializing Supplement Research

Nutritional ingredient developer ChromaDex is employing a pharma-style business model to expand its R&D into finished dietary supplements – with a long-term eye on pharmaceutical products. The firm’s recent hire of CEO Jeffrey Himmel was a significant step into the consumer products arena.

Washington State To Restrict Phthalates In Fragrance; Alternatives ‘Feasible And Available’

Personal-care and beauty products can do without fragrances that contain phthalates, says Washington Department of Ecology in a November Draft Regulatory Determinations Report to state lawmakers as per the Safer Products for Washington Act. Restriction specifics will be worked out in 2022 in consultation with stakeholders, Ecology says.

Drug Pricing Day At The US Supreme Court

Case before high court involving Medicare payment to hospitals for discounted outpatient drugs does not directly involve manufacturers. But the scope of the ruling could have a profound effect on how much leeway the government has to address drug pricing using administrative tools.

Topics

Related Companies

UsernamePublicRestriction

Register

RS125134

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel